

# Jessica R Allegretti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2957546/publications.pdf>

Version: 2024-02-01

79  
papers

3,682  
citations

196777

29  
h-index

162838

57  
g-index

83  
all docs

83  
docs citations

83  
times ranked

4188  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naïve Patients with Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2023, 68, 223-232.	1.1	3
2	Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2399-2401.e4.	2.4	23
3	Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 146-149.	0.9	8
4	Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 434-446.	0.9	14
5	Correction to: ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. <i>American Journal of Gastroenterology</i> , 2022, 117, 358-358.	0.2	1
6	Response to McFarland et al.. <i>American Journal of Gastroenterology</i> , 2022, Publish Ahead of Print, .	0.2	1
7	Effectiveness and Safety of Fecal Microbiota Transplantation for Clostridioides Difficile Infection: Results From a 5344-Patient Cohort Study. <i>Gastroenterology</i> , 2022, 163, 319-322.	0.6	18
8	Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis. <i>BMC Gastroenterology</i> , 2022, 22, 177.	0.8	4
9	Beyond Fecal Microbiota Transplantation: Developing Drugs from the Microbiome. <i>Journal of Infectious Diseases</i> , 2021, 223, S276-S282.	1.9	12
10	Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent <i>C. difficile</i> Infection. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1371-1378.	0.9	31
11	Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1627-1634.	2.4	24
12	Risk Factors that Predict the Failure of Multiple Fecal Microbiota Transplantations for Clostridioides difficile Infection. <i>Digestive Diseases and Sciences</i> , 2021, 66, 213-217.	1.1	15
13	Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. <i>Gastroenterology</i> , 2021, 160, 183-192.e3.	0.6	113
14	Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 155-161.	0.9	48
15	Fecal Microbiota Transplantation for Chronic Pouchitis: Promising Novel Therapeutic or Lost Cause?. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1873-1875.	0.9	0
16	The contribution of bile acid metabolism to the pathogenesis of <i>Clostridioides difficile</i> infection. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110177.	1.4	24
17	Ustekinumab Dose Optimization in Crohn Disease: One Size Does Not Fit All. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e70-e70.	0.9	4
18	Time to Negative SARS-CoV-2 PCR Should Not Delay Care Among Patients With Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 590-592.	0.9	0

#	ARTICLE	IF	CITATIONS
19	Costâ€effectiveness analysis of sequential fecal microbiota transplantation for fulminant <i>Clostridioides difficile</i> infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2432-2440.	1.4	8
20	SARS-CoV-2 vaccines and donor recruitment for FMT. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 264-266.	3.7	5
21	ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of <i>Clostridioides difficile</i> Infections. <i>American Journal of Gastroenterology</i> , 2021, 116, 1124-1147.	0.2	218
22	Functional Restoration of Bacteriomes and Viromes by Fecal Microbiota Transplantation. <i>Gastroenterology</i> , 2021, 160, 2089-2102.e12.	0.6	45
23	Real-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis: A Propensity Score Analysis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1694-1697.	0.9	19
24	Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2324-2332.e6.	2.4	28
25	Infliximab De-escalation in Patients With Crohnâ€™s Disease in Clinical Remission Is Safe and Well-tolerated. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 2031-2033.	0.9	3
26	Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver. <i>Canadian Liver Journal</i> , 2021, 4, 401-425.	0.3	1
27	COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1730-1732.e2.	2.4	50
28	Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity. <i>Hormones</i> , 2021, 20, 209-211.	0.9	24
29	Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 855-863.e2.	2.4	171
30	Patients Eligible for Trials of Microbe-Based Therapeutics Do Not Represent the Population With Recurrent <i>Clostridioides difficile</i> Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1099-1101.	2.4	12
31	Clinical Predictors of Recurrence After Primary <i>Clostridioides difficile</i> Infection: A Prospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1761-1766.	1.1	23
32	Fecal Microbiota Transplant Decreases Mortality in Patients with Refractory Severe or Fulminant <i>Clostridioides difficile</i> Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2234-2243.e1.	2.4	44
33	Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent <i>Clostridioides difficile</i> Infection. <i>Gastroenterology</i> , 2020, 159, 1982-1984.	0.6	28
34	Heading in the Right Dissection: Toward an Endoscopic Cancer Cure in a Patient with Long-Standing Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2818-2822.	1.1	0
35	Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent <i>Clostridioides difficile</i> infection and beyond: the contribution of gut microbial-derived metabolites. <i>Gut Microbes</i> , 2020, 12, 1810531.	4.3	32
36	Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for Treatment of Recurrent <i>Clostridioides difficile</i> Infection. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 701-706.	1.1	32

#	ARTICLE	IF	CITATIONS
37	Stool processing speed and storage duration do not impact the clinical effectiveness of fecal microbiota transplantation. <i>Gut Microbes</i> , 2020, 11, 1806-1808.	4.3	14
38	Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 430-432.	3.7	108
39	Fecal microbiota transplantation improves metabolic syndrome parameters: systematic review with meta-analysis based on randomized clinical trials. <i>Nutrition Research</i> , 2020, 83, 1-14.	1.3	57
40	Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. <i>Gut</i> , 2020, 69, 1555-1563.	6.1	110
41	Fecal transplantation for ulcerative colitis: current evidence and future applications. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 343-351.	1.4	29
42	AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 158, 1465-1496.e17.	0.6	85
43	Faecal microbiota transplantations and urinary tract infections – Authors' reply. <i>Lancet, The</i> , 2020, 395, 271.	6.3	2
44	Fecal microbiota transplantation for the treatment of recurrent and severe <i>Clostridium difficile</i> infection in solid organ transplant recipients: A multicenter experience. <i>American Journal of Transplantation</i> , 2019, 19, 501-511.	2.6	101
45	The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications. <i>Lancet, The</i> , 2019, 394, 420-431.	6.3	234
46	Donor Screening for Fecal Microbiota Transplantation. <i>New England Journal of Medicine</i> , 2019, 381, 2070-2072.	13.9	96
47	Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1343-1355.	1.4	11
48	Insights into the role of fecal microbiota transplantation for the treatment of inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481983689.	1.4	61
49	Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial. <i>American Journal of Gastroenterology</i> , 2019, 114, 1071-1079.	0.2	155
50	Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent <i>Clostridioides difficile</i> infection. <i>Gut</i> , 2019, 68, 1791-1800.	6.1	182
51	Cryptogenic Multifocal Ulcerative Sclerosing Enteritis: A Curious Case of Intestinal Obstruction in the Setting of Human Immunodeficiency Virus. <i>ACG Case Reports Journal</i> , 2019, 6, e00070.	0.2	2
52	Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: The Next Steps in This Promising Story. <i>American Journal of Gastroenterology</i> , 2019, 114, 1354-1355.	0.2	8
53	Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of <i>Clostridium difficile</i> by Fecal Microbiota Transplantation (FMT). <i>Journal of Clinical Gastroenterology</i> , 2019, 53, e405-e408.	1.1	15
54	International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2019, 68, 2111-2121.	6.1	290

#	ARTICLE	IF	CITATIONS
55	Nuts and Bolts of Fecal Microbiota Transplantation. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 345-352.	2.4	38
56	Risk of <i>Clostridium difficile</i> Infection with Systemic Antimicrobial Therapy Following Successful Fecal Microbiota Transplant: Should We Recommend Anti- <i>Clostridium difficile</i> Antibiotic Prophylaxis?. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1668-1671.	1.1	24
57	Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent <i>Clostridium difficile</i> Infection: A Comparative Cohort Analysis of High and Low Dose. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1672-1678.	1.1	48
58	Microbiome predictors of dysbiosis and VRE decolonization in patients with recurrent <i>C. difficile</i> infections in a multi-center retrospective study. <i>AIMS Microbiology</i> , 2019, 5, 1-18.	1.0	11
59	Strain Tracking Reveals the Determinants of Bacterial Engraftment in the Human Gut Following Fecal Microbiota Transplantation. <i>Cell Host and Microbe</i> , 2018, 23, 229-240.e5.	5.1	292
60	Classifying Fecal Microbiota Transplantation Failure: An Observational Study Examining Timing and Characteristics of Fecal Microbiota Transplantation Failures. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1832-1833.	2.4	23
61	Stool Donor Body Mass Index Does Not Affect Recipient Weight After a Single Fecal Microbiota Transplantation for <i>Clostridium difficile</i> Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1351-1353.	2.4	18
62	Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future. <i>Current Gastroenterology Reports</i> , 2018, 20, 14.	1.1	35
63	The 5D framework: a clinical primer for fecal microbiota transplantation to treat <i>Clostridium difficile</i> infection. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 18-29.	0.5	41
64	Small Intestinal Bacterial Overgrowth: Should Screening Be Included in the Pre-fecal Microbiota Transplantation Evaluation?. <i>Digestive Diseases and Sciences</i> , 2018, 63, 193-197.	1.1	13
65	Early Antibiotic Use After Fecal Microbiota Transplantation Increases Risk of Treatment Failure. <i>Clinical Infectious Diseases</i> , 2018, 66, 134-135.	2.9	38
66	533. Scaling Pediatric Access to Fecal Microbiota Transplantation in the United States: A Time-Series Geospatial Analysis. <i>Open Forum Infectious Diseases</i> , 2018, 5, S197-S197.	0.4	1
67	618. Do Clinical Factors Affect Microbial Engraftment After Fecal Microbiota Transplantation in Recurrent <i>Clostridium difficile</i> Infection?. <i>Open Forum Infectious Diseases</i> , 2018, 5, S225-S226.	0.4	2
68	Endospores and other lysis-resistant bacteria comprise a widely shared core community within the human microbiota. <i>ISME Journal</i> , 2018, 12, 2403-2416.	4.4	40
69	Legalization of Medicinal Marijuana Has Minimal Impact on Use Patterns in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2309-2314.	0.9	16
70	Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1590-1596.	1.1	56
71	The Current Landscape and Lessons from Fecal Microbiota Transplantation for Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1710-1717.	0.9	39
72	The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis. <i>Gut Microbes</i> , 2017, 8, 574-588.	4.3	102

#	ARTICLE	IF	CITATIONS
73	FMT in IBD: What Have We Learned?. Digestive Diseases and Sciences, 2017, 62, 2618-2620.	1.1	2
74	Faecal microbiota transplantation for <i>Clostridium difficile</i> infection: a multicentre study of non-responders. Medical Journal of Australia, 2017, 207, 159-160.	0.8	5
75	Clearance of Vancomycin-Resistant Enterococcus Colonization With Fecal Microbiota Transplantation Among Patients With Recurrent <i>Clostridium difficile</i> Infection. Open Forum Infectious Diseases, 2016, 3, .	0.4	8
76	Are Patients with Inflammatory Bowel Disease on Chronic Immunosuppressive Therapy at Increased Risk of Cervical High-grade Dysplasia/Cancer? A Meta-analysis. Inflammatory Bowel Diseases, 2015, 21, 1089-1097.	0.9	112
77	Risk Factors for Rehospitalization Within 90 Days in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 2583-2589.	0.9	45
78	Fecal Microbiota Transplantation via Colonoscopy for Recurrent <i>C. difficile</i> Infection. Journal of Visualized Experiments, 2014, , .	0.2	22
79	Oral microbes effective for prevention of recurrent <i>Clostridium difficile</i> infections. , 0, , .		0